- Home
- PHIO vs SNSE Comparison
PHIO vs SNSE Comparison
Compare PHIO & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- SNSE
- Stock Information
- Founded
- PHIO 2011
- SNSE 2005
- Country
- PHIO United States
- SNSE United States
- Employees
- PHIO N/A
- SNSE N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- SNSE Health Care
- Exchange
- PHIO Nasdaq
- SNSE Nasdaq
- Market Cap
- PHIO 11.9M
- SNSE 10.8M
- IPO Year
- PHIO N/A
- SNSE 2021
- Fundamental
- Price
- PHIO $2.51
- SNSE $7.16
- Analyst Decision
- PHIO Strong Buy
- SNSE Strong Buy
- Analyst Count
- PHIO 2
- SNSE 3
- Target Price
- PHIO $9.00
- SNSE $86.67
- AVG Volume (30 Days)
- PHIO 118.9K
- SNSE 8.7K
- Earning Date
- PHIO 08-13-2025
- SNSE 08-05-2025
- Dividend Yield
- PHIO N/A
- SNSE N/A
- EPS Growth
- PHIO N/A
- SNSE N/A
- EPS
- PHIO N/A
- SNSE N/A
- Revenue
- PHIO N/A
- SNSE N/A
- Revenue This Year
- PHIO N/A
- SNSE N/A
- Revenue Next Year
- PHIO N/A
- SNSE N/A
- P/E Ratio
- PHIO N/A
- SNSE N/A
- Revenue Growth
- PHIO N/A
- SNSE N/A
- 52 Week Low
- PHIO $0.97
- SNSE $5.00
- 52 Week High
- PHIO $9.79
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- PHIO 56.49
- SNSE 38.57
- Support Level
- PHIO $2.31
- SNSE $7.62
- Resistance Level
- PHIO $2.45
- SNSE $8.42
- Average True Range (ATR)
- PHIO 0.13
- SNSE 0.60
- MACD
- PHIO 0.00
- SNSE -0.23
- Stochastic Oscillator
- PHIO 64.52
- SNSE 11.30
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).